Skip to main content
Vyome Holdings, Inc logo

Vyome Holdings, Inc — Investor Relations & Filings

Ticker · HIND ISIN · US67424L2097 US Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2025-01-21 Capital/Financing Update
Country US United States of America
Listing US HIND

About Vyome Holdings, Inc

https://www.reshapelifesciences.com/oba…

Vyome Holdings, Inc. is a clinical-stage biotechnology company focused on developing a portfolio of assets for immuno-inflammatory and potential orphan diseases. The company utilizes an artificial intelligence (AI)-driven platform to accelerate its research and development pipeline. Its operations are structured to leverage innovation and R&D capabilities across both the United States and India.

Recent filings

Filing Released Lang Actions
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to a securities purchase agreement involving a convertible note and changes to its terms. There is no detailed financial data or comprehensive financial statements, nor is it an annual or quarterly report. The document is primarily an announcement of a material definitive agreement amendment related to financing. This fits best under Capital/Financing Update (CAP) as it concerns changes to the company's capital structure and financing arrangements. The document length is 4611 characters, which is consistent with a detailed announcement rather than a brief notice or a full report. Therefore, the classification is CAP with high confidence.
2025-01-21 English
S-4/A Filing
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form S-4 Registration Statement filed with the SEC, which includes a proxy/information statement-prospectus related to a merger transaction between ReShape Lifesciences Inc. and Vyome Therapeutics Inc. It contains detailed information about the merger agreement, special meeting of stockholders, voting proposals, and related corporate actions. The document is not a simple announcement but a comprehensive filing combining proxy solicitation materials and merger-related disclosures. This type of document fits the category of Proxy Solicitation & Information Statement (PSI), as it is designed to provide shareholders with information and request votes for the merger-related proposals at a special meeting. The length (15,000 characters) and content confirm it is not a brief announcement or a simple regulatory filing. Therefore, the appropriate classification is PSI with high confidence.
2025-01-15 English
S-1/A Filing
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement Amendment No. 1 filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes detailed information about the company, its business, growth strategies, product portfolio, and legal matters, typical of a prospectus and registration statement. This is not an annual report, earnings release, or any other financial report but a capital markets filing related to a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2025-01-15 English
SCHEDULE 13D Filing
Major Shareholding Notification
2025-01-07 English
8-K Filing
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC by ReShape Lifesciences Inc. dated December 27, 2024, reporting the entry into a material definitive agreement, specifically an equity purchase agreement for up to $5 million of common stock over 36 months. It details terms of the agreement, issuance of shares and warrants, Nasdaq listing rules compliance, and references a Registration Statement on Form S-1 filed subsequently. The document is a current report disclosing a significant financing transaction and related equity issuance, not a full financial report or earnings release. It is not an annual or quarterly report, audit report, or management discussion. The content fits the category of Capital/Financing Update as it provides detailed information on a financing agreement and equity issuance. The document length (11,991 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-12-27 English
S-1 Filing
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for the resale of shares by a selling stockholder and includes detailed information about the equity financing transaction, convertible note transaction, selling stockholder, use of proceeds, risk factors, and plan of distribution. The document is not an annual report, earnings release, or any other financial report but rather a registration statement for securities offering. This type of filing corresponds to a capital raising or financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed substantive information about the offering, not just an announcement or notice, supporting a high confidence level.
2024-12-20 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.